Outcome of therapy for bladder cancer patients is dependent on the stage at which cancer is diagnosed. Bladder cancer cases have a 5-year survival rate of 36% and 6% for regional and distant spread of the disease respectively. A previous study identified L-selectin (CD-62L) as a potential protein biomarker indicative of aggressive bladder cancer. This work focuses on quantifying CD-62L expression in patients with varied progression of the disease, as high-grade muscle invasive tumor cases exhibit overexpression of this protein. A sensitive amperometric microfluidic immunoarray for multiplexed biomarker protein detection is described here, which employs modified sandwich immunoassays. Analyte proteins with detection antibodies on enzyme-label decorated magnetic beads are captured online, followed by incubation with surface bound capture antibody on an 8-electrode screen-printed carbon array. A hydroquinone/hydrogen peroxide activator/mediator mixture is injected for amperometric signal detection. Current efforts are directed towards simultaneous detection of ng/ml levels CD-62L along with fg/ml levels of Interleukin-6 (IL-6) as a benchmark. The combination of electrochemical detection with microfluidics provides a cost-efficient, flexible and effective tool for bladder cancer diagnostics.

Simultaneous microfluidic assays for quantitation of CD-62L and IL-6 protein biomarkers for metastatic bladder cancer

251st National Meeting (2016)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.